The global preimplantation genetics diagnosis (PGD) market is projected to grow significantly during the forecast period owing to the rising incidences of hereditary, genetic, and chromosomal diseases. PGD is evolving as a promising technique to prevent the substantial risk of transmitting a severe genetic disorder to their offspring. The market is projected to see gradual growth owing to rising warenes about its benefits. Significant improvements in PGD analysis, such as fluorescence in situ hybridization (FISH), to newer molecular tools, such as DNA microarrays and next-generation sequencing will create new opportunities for the market. However, the high costs incurred in the PGD procedure hinder the growth of the market. Moreover, ethical concerns also obstruct the growth of the market.
The entire preimplantation genetics diagnosis (PGD) market has been sub-categorized into test type. demand for preimplantation genetics diagnosis (PGD) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
By Test Type
- Chromosomal Abnormalities
- Gender Selection
- X-linked Diseases
- Aneuploidy
- Single Gene Disorders
- Others
The major players in the preimplantation genetics diagnosis (PGD) market include Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., Reproductive Genetics Innovations LLC.
Source: https://www.valuemarketresearch.com/report/preimplantation-genetics-diagnosis-pgd-market
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.